Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00403-025-04136-8 | DOI Listing |
Publication Analysis
Top Keywords
correction ritlecitinib
4
ritlecitinib jak3
4
jak3 /tec
4
/tec inhibitor
4
inhibitor modulates
4
modulates markers
4
markers celiac
4
celiac autoimmunity
4
autoimmunity alopecia
4
alopecia areata
4
Similar Publications
Correction: Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Arch Dermatol Res
March 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
Am J Clin Dermatol
July 2024
Pfizer Inc, 23 Av. du Dr Lannelongue, 75014, Paris, France.
Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
AAPS J
February 2024
Pharmaceutical Science, Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, CT, 06340, USA.
Correction to: Ritlecitinib: First Approval.
Drugs
October 2023
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!